Jeil Pharm
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms i… Read more
Jeil Pharm (002620) - Total Liabilities
Latest total liabilities as of September 2025: ₩400.33 Billion KRW
Based on the latest financial reports, Jeil Pharm (002620) has total liabilities worth ₩400.33 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Jeil Pharm - Total Liabilities Trend (2011–2024)
This chart illustrates how Jeil Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Jeil Pharm Competitors by Total Liabilities
The table below lists competitors of Jeil Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Puriblood Medical Co., Ltd.
TWO:6847
|
Taiwan | NT$90.33 Million |
|
Carriesoft Co. Ltd
KQ:317530
|
Korea | ₩8.75 Billion |
|
Foresta Group Holdings Ltd
AU:FGH
|
Australia | AU$2.89 Million |
|
Donegal Investment Group PLC
IR:DQ7A
|
Ireland | €14.60 Million |
|
US Energy Corp
NASDAQ:USEG
|
USA | $21.46 Million |
|
Senheng New Retail Bhd
KLSE:5305
|
Malaysia | RM293.07 Million |
|
The Market Ltd
AU:MKT
|
Australia | AU$92.86 Million |
|
Asefa Public Company Limited
BK:ASEFA
|
Thailand | ฿2.43 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Jeil Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jeil Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jeil Pharm (2011–2024)
The table below shows the annual total liabilities of Jeil Pharm from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩453.04 Billion | -5.19% |
| 2023-12-31 | ₩477.81 Billion | +7.16% |
| 2022-12-31 | ₩445.88 Billion | +13.71% |
| 2021-12-31 | ₩392.11 Billion | +1.03% |
| 2020-12-31 | ₩388.11 Billion | +6.79% |
| 2019-12-31 | ₩363.44 Billion | +9.96% |
| 2018-12-31 | ₩330.51 Billion | +1117.39% |
| 2017-12-31 | ₩27.15 Billion | -88.68% |
| 2016-12-31 | ₩239.91 Billion | +17.73% |
| 2015-12-31 | ₩203.78 Billion | +36.43% |
| 2012-12-31 | ₩149.36 Billion | -2.21% |
| 2011-12-31 | ₩152.74 Billion | -- |